



**Vaccines and Global Health: The Week in Review**  
**16 March 2024 :: Issue 742**  
**Center for Vaccine Ethics & Policy (CVEP)**

*This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.*

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.*

*Comments and suggestions should be directed to*

*David R. Curry, MS*

*Editor and*

*Executive Director*

*Center for Vaccine Ethics & Policy*

*[david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)*

***Request email delivery of the pdf:*** *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org).*

***Support this knowledge-sharing service:*** *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

***Contents [click to move among sections]***

*:: [Milestones, Perspectives](#)*

*:: [WHO](#)*

*:: [Organization Announcements](#)*

*:: [Journal Watch](#)*

*:: [Pre-Print Servers](#)*

*:: [Think Tanks](#)*

## ***Milestones, Perspectives***

.....  
.....

### **[Ninth meeting of the Intergovernmental Negotiating Body \(INB\) for a WHO instrument on pandemic prevention, preparedness and response](#)**

**18 – 28 March 2024**

09:00–12:00, 13:00–16:00 and 16:30–18:30 CET, Geneva, Switzerland

In December 2021, the World Health Assembly established an Intergovernmental Negotiating Body (INB) to draft and negotiate a convention, agreement or other international instrument under the Constitution of the World Health Organization to strengthen pandemic prevention, preparedness and response.

The ninth meeting of the INB is to be held in hybrid format from 18 to 28 March 2024. At INB8, Member States requested the INB Bureau, formed by six officers, one from each of the six WHO regions, to develop a revised draft of the negotiating text of the WHO Pandemic Agreement. This draft will be the basis of textual negotiations at INB9.

The opening and closing plenary sessions of the INB are open to WHO Member States, Associate Members, Observers and regional economic integration organizations, as well all relevant stakeholders. These sessions will be publicly webcast and archived for later viewing. Substantive negotiating sessions will be held in closed format.

[A/INB/9/1](#) - Provisional agenda

[A/INB/9/2](#) - Draft programme of work

[A/INB/9/3](#) - Revised draft of the negotiating text of the WHO Pandemic Agreement

.....  
.....

### **[Delivering equitable access in pandemics: Biopharmaceutical industry commitments](#)**

*Joint Statement* [ IFPMA, BIO, DCVMN, EFPPI, JPMA, PhRMA

11 Mar 2024

*The 77th World Health Assembly (WHA) marks the deadline for the conclusion of a pandemic agreement and amended International Health Regulations (2005) that seek to make the world better prepared for the next pandemic.*

**In response to the threat of future global pandemics, the biopharmaceutical industry developed a set of commitments for equitable access to essential medical countermeasures in future pandemics.** Demonstrating the commitment of the private sector to prioritize the needs of all individuals and communities affected in a pandemic, companies are prepared to leverage their individual expertise and resources to address the challenges posed by pandemics and ensure that no one is left behind. This represents a significant step forward in promoting equity and inclusivity in the distribution of vital resources.

Achieving equitable access to medical countermeasures requires a comprehensive solution and should not be based on linking access to pathogen samples and sequence data to benefit-sharing obligations. It is critical to preserve the innovation ecosystem and research incentives that were

effective in the fight against COVID-19. Scientists need rapid access to pathogens and data without conditions in order to quickly develop safe and effective countermeasures to save lives.

### ***Equitable Access Commitments in the pandemic agreement***

Building on the commitment contained in the Berlin Declaration, we support that the pandemic agreement creates a broad multistakeholder Partnership for Equitable Access to which companies can voluntarily associate through their adoption of a range of Equitable Access Commitments, which would be legally binding and enforceable through contracts.

Companies could independently adopt one or more of the following Equitable Access Commitments in periods in between pandemics and/or during pandemics based on what each company could best contribute in view of its circumstances, such as its size, location, technology platform, research and development pipeline, or manufacturing capabilities.

#### **In pre-pandemic time, commitments to commence, continue, or enhance:**

- Basic or applied research and development (R&D) on vaccines or therapeutics against pathogens of pandemic potential, including through the use of novel technologies such as artificial intelligence, supercomputing, and robotics;
- Novel platform technologies, with the goal of having multiple platforms ready for a pandemic and exploring collaborations with relevant public and private entities, especially in low-income countries (LICs) and lower-middle-income countries (LMICs);
- Geographically diverse and comprehensive clinical trial sites and networks, including through expanding clinical research sites in underserved areas;
- Manufacturing and/or distribution capacity for relevant therapeutics or vaccines, including through public and/or private partnerships, supply agreements, or voluntary technology transfer agreements, in support of globally enhanced manufacturing and fill/finish capacity;
- Financial and technical support to LICs and LMICs for capacity building for pandemic preparedness and response, including genomic, environmental, or laboratory disease surveillance; establishing or enhancing clinical trial capacity; strengthening and retention of the health workforce; strengthening regulatory systems; or running additional laboratory capacities that might be relevant.

#### **After a pandemic is declared, commitments to:**

- Reserve a percentage of real time production volume of a relevant therapeutic or vaccine for equitable distribution on the basis of public health risks, needs, and demand. This could include a portion expected as a donation to LICs and/or a portion negotiated under equity-based tiered pricing with the lowest tiers dedicated to LICs and LMICs. In the case of a Repurposed Medicinal Product, attention should be taken to ensure security of supply for care of patients who continue to need the product for its existing indications and uses;
- Rapid scale-up of production and distribution capabilities, where possible in geographically diverse locations. This may include enhancing the availability of raw materials, active pharmaceutical ingredients, or consumables for the manufacturing of relevant therapeutics or vaccines, and may be done in collaboration with relevant WHO programs;
- Leverage voluntary license and technology transfer partnerships to ensure that their innovative medical countermeasures reach patients, with special attention to the needs of LICs and LMICs;
- Establish, enhance, and prioritize research efforts to identify candidate vaccines as well as new and/or repurposed therapeutics relevant to the pandemic;
- Make its library of molecules available to relevant third parties on fair conditions for the purpose of developing a relevant therapeutic or vaccine;
- Lend financial and technical support to LMICs for capacity building to support research, manufacturing, or supply for relevant therapeutics or vaccines;

- Collaborate with the WHO and others on treatment guidelines for relevant audiences to optimize delivery and administration of relevant therapeutics or vaccines.

## Enablers

The pandemic agreement provides a unique opportunity to establish a comprehensive system for better and more equitable pandemic preparedness and response. For the Partnership to deliver on its mission, four enablers are of particular importance:

- All countries, but specifically those governments of countries with manufacturing facilities, commit, through the pandemic agreement, to allow for unrestricted exports of pandemic medical countermeasures, manufacturing inputs, and raw materials.
- Strong regulatory systems and the use of regulatory strategies ensure the accelerated availability of pandemic vaccines and treatments, in line with the G7 100 Days Mission. Internationally harmonized and streamlined approvals will be instrumental in improving equitable access. Member states need to facilitate distribution of donations by ensuring that such products are approved for use in that Member State, including through WHO Emergency Use Listing, prequalification, or based on reliance on approval by a stringent regulatory authority.
- Unconditional access to pathogens and relevant data and recognition of the pandemic agreement as a Special International Instrument (SII) in accordance with the Nagoya Protocol, thereby mitigating the delays caused by national access and benefit-sharing laws.
- Inclusive governance through a Partnership where WHO has a central role but also encompasses all stakeholders that will contribute to the implementation of the agreement, including industry, in roles appropriate to their capacity and expertise.



## **Multi-country outbreak of cholera, External situation report #12 - 14 March 2024**

Edition 12

14 March 2024 | Emergency Situational Updates

### *Overview*

Since the beginning of 2023, a cumulative total 787 813 cholera cases and 5586 deaths have been reported from 31 countries across five WHO regions, with the Eastern Mediterranean region recording the highest numbers, followed by the African, South-East Asia, Americas, and Western Pacific regions. No outbreaks have been reported in the European Region during this period.

**The global cholera response continues to be affected by a critical shortage of Oral Cholera Vaccines (OCV). From January 2023 to February 2024, requests for OCV have surged, with 79 million doses requested by 14 countries, double the 40 million doses available during that period. The global stockpile of vaccines is awaiting replenishment and all production up to 4 March has been allocated to requests already approved.**

WHO classified the global resurgence of cholera as a grade 3 emergency in January 2023, its highest internal level for emergencies. Based on the number of outbreaks and their geographic expansion, alongside the shortage of vaccines and other resources, WHO continues to assess the risk at the global level as very high and the event remains classified as a grade 3 emergency.

*For the latest data, please refer to the new [WHO Global Cholera and AWD Dashboard](#).  
Cholera upsurge (2021-present): <https://www.who.int/emergencies/situations/cholera-upsurge/>*



## [PAHO and countries of the Americas seek to establish an intersectoral commission to prevent and control avian influenza](#)

Río de Janeiro, Brazil, 14 March 2024 (PAHO) – In order to strengthen surveillance, prevention and control of avian influenza in both animals and humans, the **Pan American Health Organization (PAHO) convened its 35 member states in Brazil this week to establish a regional commission to combat the disease.** The meeting took place at a time when the world is experiencing high levels of transmission of the virus among birds and mammals, which poses a potential risk to public health...

**The Inter-sectoral Commission for the Prevention and Control of Avian Influenza in the Americas will enable public, animal and environmental health sectors to exchange updated information on surveillance, epidemiological risk and evolution of circulating viruses. The commission is also expected to promote strategies at the national, sub-regional and regional levels** and strengthen coordination...

The new Commission will comprise specialists in the areas of seasonal influenza, zoonosis, pandemics, epidemiology and laboratory from ministries of health in the Americas. It will also include veterinary officials, representatives of the environmental sector, and collaborating centers, with PAHO acting as secretariat...

Also participating in the meeting this week were representatives of several organizations, including the Food and Agriculture Organization of the United Nations (FAO), the Inter-American Institute for Cooperation on Agriculture (IICA), the International Regional Organization for Plant and Animal Health (OIRSA), the Caribbean Animal Health Network (CaribVET), the Executive Secretariat of the Council of Ministers of Health of Central America and the Dominican Republic (SE-COMISCA), the U.S. Centers for Disease Control and Prevention (CDC), the U.S. Animal and Plant Health Inspection Service (APHIS) and WHO collaborating centers for human and animal influenza.

.....  
.....

## [Levels and trends in child mortality: Report 2023](#)

United Nations Inter-Agency Group for Child Mortality Estimation (UN IGME)  
March 12, 2024


This year's United Nations Inter-agency Group for Child Mortality Estimation (UN IGME)'s findings represent a noteworthy moment in the ongoing campaign to end all preventable child deaths: The annual number of under-five deaths has fallen to 4.9 (4.6–5.4) million in 2022.

**The report reveals that more children are surviving today than ever before, with the global under-5 mortality rate declining by 51 per cent since 2000.** And several low- and lower-middle-income countries have outpaced this decline. This is a testament to the commitment of governments, organizations, local communities, health-care professionals and families to the survival of the most vulnerable members of our global community.

**Yet millions of children still died before seeing their fifth birthday** – a loss that serves as a crucial reminder that threats to newborn and child health and survival persist around the world, particularly among the most marginalized children. In addition to the 4.9 million lives lost before the age of 5 – nearly half of which were newborns – the lives of another 2.1 million children and youth aged 5-24 were also cut short. **Most of these deaths were concentrated in sub-Saharan Africa and Southern Asia.** There is still a long road ahead to end all preventable child and youth deaths.

**Ending preventable child deaths in every community will require targeted investments in available, accessible quality health care,** including skilled health personnel at birth, antenatal and postnatal care, care for small and sick newborns, **preventive services such as vaccination,** and diagnostic, preventive and curative measures to treat the key causes of childhood death. Data systems must also be strengthened to track and monitor survival by age and to help address underlying inequalities. This will enable us to move closer to achieving the Sustainable Development Goals and ensure that every child has the opportunity to thrive.

Report PDF: <https://data.unicef.org/resources/levels-and-trends-in-child-mortality-2024/>



.....  
 .....  
 .....

## Polio – PHEIC

### Polio this week as of 13 Mar 2024 - GPEI

#### ***Summary of new polioviruses this week, cases and positive environmental isolates:***

- Angola: one cVDPV2-positive environmental sample
- Côte d’Ivoire: four cVDPV2-positive environmental samples
- Mali: one cVDPV2 case
- Nigeria: one cVDPV2 case

- Sierra Leone: one cVDPV2-positive environmental sample
- Yemen: three cVDPV2 cases



***Contents [click to move among sections]***

*:: [Milestones, Perspectives](#)*

*:: [WHO](#)*

*:: [Organization Announcements](#)*

*:: [Journal Watch](#)*

*:: [Pre-Print Servers](#)*



**WHO & Regional Offices** [to 16 Mar 2024]

<https://www.who.int/news>

*Selected News/Announcements/Statements*

13 March 2024 Joint News Release

**[WHO and UNICEF launch free online course to address children's environmental health](#)**

13 March 2024 Joint News Release

**[Global child deaths reach historic low in 2022 – UN report](#)**

13 March 2024 Departmental news

**[WHO BPaLM Accelerator Platform](#)**

The WHO BPaLM Accelerator Platform was established in January 2023, right after the update of WHO guidelines on the treatment of drug-resistant TB in 2022. The purpose of the WHO BPaLM Accelerator Platform is to support countries and stakeholders in information exchange and technical discussions to address challenges in the adoption and implementation of the BPaLM/BPaL regimen. This is also to support the Call to Action on rolling out of the BPaLM regimen and other short regimens for treatment of TB that was initiated by WHO and its multiple partners.

10 March 2024 Departmental news

**[How to give voice to citizens in evidence-informed policy processes?](#)**



**WHO Regional Offices**

*Selected Press Releases, Announcements*

**[WHO African Region](#)**

:: 13 March 2024

**[Liberia rewriting cervical cancer narrative, one dose at a time](#)**

**[WHO Region of the Americas PAHO](#)**

:: 14 Mar 2024

**[PAHO and countries of the Americas seek to establish an intersectoral commission to prevent and control avian influenza](#)**

**[WHO South-East Asia Region SEARO](#)**

*No new digest content identified.*

## **WHO European Region EURO**

*No new digest content identified.*

## **WHO Eastern Mediterranean Region EMRO**

:: **Unprecedented number of Syrians in need of aid after 13 years of war**

16 March 2024

:: **Regional Director statement on Sudan**

15 March 2024

:: **WHO builds Egypt's capacities to manage and analyse health data**

13 March 2024

:: **Sudan to respond to new emergence of variant poliovirus in Red Sea State**

11 March 2024

## **WHO Western Pacific Region**

*No new digest content identified.*

.....

## **WHO - Emergency situation reports**

*Latest WHO official reports for emergency situations.*

14 March 2024

**Multi-country outbreak of cholera, External situation report #12 - 14 March 2024**

.....

## **Disease Outbreak News (DONs)**

*Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.*

*No new digest content identified.*

.....

## **Weekly Epidemiological Record**

<https://www.who.int/publications/journals/weekly-epidemiological-record>

**Vol. 99, No. 11, pp. 115–134 15 March 2024**

<https://iris.who.int/bitstream/handle/10665/376282/WER9911-eng-fre.pdf>

:: Mumps vaccines

.....

## **New WHO Publications**

<https://www.who.int/publications/i>

*Selected*

15 March 2024

**Mumps virus vaccines: WHO Position Paper, March 2024**

13 March 2024

**Handbook for non-State actors on engagement with the World Health Organization, second edition**

13 March 2024



**[Report of the eighth meeting of the Strategic and Technical Advisory Group of Experts for Maternal, Newborn,...](#)**

11 March 2024

**[Laboratory biosafety guidance related to SARS-CoV-2 \(COVID-19\): Interim guidance, 11 March 2024](#)**

.....  
.....

**USA – HHS, FDA, CDC**

**HHS**

*[News](#)*

*No new digest content identified.*

**FDA**

*[Press Announcements](#)*

**[FDA Roundup: March 15, 2024](#)**

Today, the FDA published its new paper, "[Artificial Intelligence and Medical Products: How CBER, CDER, CDRH, and OCP are Working Together](#)," which outlines specific focus areas regarding the development and use of AI across the medical product lifecycle. The paper helps further align and streamline the agency's work in AI. Read more about the agency's AI initiatives on our [website](#).

**FDA VRBPAC**

*[Advisory Committee Calendar](#)*

**[Vaccines and Related Biological Products Advisory Committee May 16, 2024 Meeting Announcement - 05/16/2024](#)**

**CDC/ACIP [U.S.] [to 16 Mar 2024]**

<http://www.cdc.gov/media/index.html>

*[Latest News Releases](#)*

*No new digest content identified.*

**[ACIP Meetings](#)**

*[Next ACIP Meeting](#)*

June 26-28

**MMWR Weekly**

<https://www.cdc.gov/mmwr/index2023.html>

**March 14, 2024 / No. 10**

[PDF of this issue](#)

- [Notes from the Field: Surveillance for Multisystem Inflammatory Syndrome in Children — United States, 2023](#)
- [Notes from the Field: Measles Outbreak — Cook County, Illinois, October–November 2023](#)

.....  
.....

**Europe**

**European Medicines Agency [EMA]**

<https://www.ema.europa.eu/en/news>

*News & Press Releases*

*No new digest content identified.*

## **European Centre for Disease Prevention and Control**

<https://www.ecdc.europa.eu/en>

*News/Updates/Reports/Publications [Selected]*

*Scientific and technical publications*

### **[Communicable disease threats report, 10-16 March 2024, week 11](#)**

15 Mar 2024

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 10-16 March 2024 and includes updates on SARS-CoV-2 variant classification, avian influenza, measles, cholera, and overview of respiratory virus epidemiology in the EU/EE.

*Scientific and technical publications*

### **[Protocol for a COVID-19 vaccine effectiveness multi-country cohort study in the paediatric population aged 5–17-years using electronic health records in EU/EEA countries](#)**

15 Mar 2024

This protocol describes the common methodology to be applied to established health data registries across seven participating EU/EEA Member States to estimate vaccine effectiveness for Coronavirus disease 2019 (COVID-19) in children and adolescents aged 5-17 years old.

.....

.....

## **Africa CDC** [to 16 Mar 2024]

<https://africacdc.org/>

*Press Releases, Statements [Selected]*

### **[Opinion: Africa needs a win from the pandemic agreement negotiations](#)**

16 March 2024

.....

.....

## **China CDC**

<http://www.chinacdc.cn/en/>

## **National Health Commission of the People's Republic of China** [to 16 Mar 2024]

<http://en.nhc.gov.cn/>

*News*

*No new digest content identified.*

## **National Medical Products Administration – PRC** [to 16 Mar 2024]

<http://english.nmpa.gov.cn/>

*News*

*No new digest content identified.*

## **China CDC**

### **[Weekly Reports: Current Volume \(6\)](#)**

2024-03-15 / No. 11 ***LIFE COURSE HEALTH ISSUE***

[View](#) [PDF of this issue](#)

No new digest content identified.

.....  
.....

### **Contents [click to move among sections]**

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....  
.....

### **Organization Announcements**

**Paul G. Allen Frontiers Group** [to 16 Mar 2024]

<https://alleninstitute.org/news-press/>

News

No new digest content identified.

**BMGF - Gates Foundation** [to 16 Mar 2024]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases and Statements

No new digest content identified.

**Bill & Melinda Gates Medical Research Institute** [to 16 Mar 2024]

<https://www.gatesmri.org/news>

*The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people*

News: Articles and Publications

No new digest content identified.

**CARB-X** [to 16 Mar 2024]

<https://carb-x.org/>

News

No new digest content identified.

**CEPI – Coalition for Epidemic Preparedness Innovations** [to 16 Mar 2024]

<http://cepi.net/>

Latest News

News

[New 'spin freezing' technique could enhance future mRNA vaccines](#)

10 Mar 2024

News

**Global consortium plans coordinated human challenge studies in hunt for transmission-blocking coronavirus vaccines**

10 Mar 2024

- \$57 million project will test inhaled and nasal vaccines designed to stop viral infection
  - Human challenge studies uniquely able to progress such transmission-blocking vaccines
  - Coordinated trials involve safely inducing infection in small groups of healthy volunteers
- OSLO/LONDON, March 11, 2024 - An international consortium of researchers specialising in human challenge studies is embarking on a US\$57 million project to develop advanced, virus-blocking coronavirus vaccines that could stop SARS-CoV-2 and other coronaviruses from infecting people in the first place.

Led by Imperial College London and co-funded by the European Union's Horizon Europe Programme and CEPI, the Coalition for Epidemic Preparedness Innovations, the consortium of more than a dozen scientific teams and organisations will begin by running trials to select particular viruses and identify the best conditions under which to safely induce infection in healthy volunteers. A human challenge study is a carefully managed medical research study, during which volunteers are intentionally given an infection in a safe way, with healthcare support.

Researchers at multiple clinical research facilities will then use a selected virus to try to infect healthy volunteers who have received an experimental vaccine. Unlike traditional vaccines which are injected into muscle, these experimental vaccines will be inhaled into the lungs or sprayed in the nose and are designed to induce a type of protection known as mucosal immunity – which scientists believe could be the key to stopping onward transmission of coronaviruses...

**CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES** [to

16 Mar 2024]

<https://cioms.ch/>

*News; Publications; Events*

*No new digest content identified.*

**DARPA – Defense Advanced Research Projects Agency [U.S.]** [to 16 Mar 2024

<https://www.darpa.mil/news>

*News*

*No new digest content identified.*

**Duke Global Health Innovation Center** [to 16 Mar 2024]

<https://dukeghic.org/>

*News*

*No new digest content identified.*

**EDCTP** [to 16 Mar 2024]

<http://www.edctp.org/>

*The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials*

*News*

12 March 2024

**[An innovative and integrated intervention package delivered through the health system could protect infants from HIV](#)**

**Emory Vaccine Center** [to 16 Mar 2024]

<http://www.vaccines.emory.edu/>

*Vaccine Center News*

*No new digest content identified.*

**European Vaccine Initiative** [to 16 Mar 2024]

<http://www.euvaccine.eu/>

*Latest News, Events*

*No new digest content identified.*

**Evidence Aid** [to 16 Mar 2024]

*Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.*

<http://www.evidenceaid.org/>

*Resources [Selected]*

**[Telehealth interventions for COVID-19 in sub-Saharan Africa](#)**

Added March 9, 2024

**Fondation Merieux** [to 16 Mar 2024]

<http://www.fondation-merieux.org/>

*News, Events*

*No new digest content identified.*

**Gavi** [to 16 Mar 2024]

<https://www.gavi.org/>

*News Releases*

*No new digest content identified.*

**GE2P2 Global Foundation** [to 16 Mar 2024]

[www.ge2p2.org](http://www.ge2p2.org)

*News/Analysis/Publications-Digests/Statements*

:: [Vaccines and Global Health: The Week in Review](#) - Current edition

:: [Informed Consent: A Monthly Review – March 2024](#)

:: [Genomic Medicine – Governance, Ethics, Policy, Practice: A Monthly Digest](#) – Oct 2023

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 07 March 2024 – Issue 14](#)

**GHIT Fund** [to 16 Mar 2024]

<https://www.ghitfund.org/newsroom/press>

*Press Releases*

*No new digest content identified.*

**Global Fund** [to 16 Mar 2024].

<https://www.theglobalfund.org/en/news/>

*News & Stories*

*No new digest content identified.*

**Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]** [to 16 Mar 2024]

<https://www.glopid-r.org/news/>

*News*

*No new digest content identified.*

**Hilleman Laboratories** [to 16 Mar 2024]

<http://www.hilleman-labs.org/>

*News & Insights*

*No new digest content identified.*

**HHMI - Howard Hughes Medical Institute** [to 16 Mar 2024]

<https://www.hhmi.org/news>

*Press Room*

### **[Scaling Up Precision Genome Editing](#)**

Precision genome editing tools – including prime editing – enable scientists to model genetic variants in their native environment. Now, researchers have developed a framework for engineering and measuring the effects of thousands of genetic mutations simultaneously while accurately quantifying the efficiency of prime editing. They've even found that some mutations once considered to be inconsequential or nonpathogenic may contribute to cancers.

March 15, 2024

**Human Immunome Project [nee Human Vaccines Project]** [to 16 Mar 2024]

<http://www.humanvaccinesproject.org/>

*News*

*No new digest content identified.*

**IAVI** [to 16 Mar 2024]

<https://www.iavi.org/>

*News, Features*

*No new digest content identified.*

**INSERM** [to 16 Mar 2024]

<https://www.inserm.fr/en/home/>

*Press Releases*

*No new digest content identified.*

**International Coalition of Medicines Regulatory Authorities [ICMRA]**

<http://www.icmra.info/drupal/en/news>

*Selected Statements, Press Releases, Research*

*No new digest content identified.*

**ICH - International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use** [to 16 Mar 2024]

<https://www.ich.org/page/press-releases>

*News/Pubs/Press Releases [Selective]*

*No new digest content identified.*

**ICRC** [to 16 Mar 2024]

<https://www.icrc.org/en/whats-new>

*What's New [Selected]*

*No new digest content identified.*

**IFFIm**

<http://www.iffim.org/>

*Press Releases/Announcements*

*No new digest content identified.*

**IFRC** [to 16 Mar 2024]

<http://media.ifrc.org/ifrc/news/press-releases/>

*Press Releases [Selected]*

*No new digest content identified.*

**Institut Pasteur** [to 16 Mar 2024]

<https://www.pasteur.fr/en/press-area>

*Press Documents*

*No new digest content identified.*

**ISC / International Science Council** [to 16 Mar 2024]

<https://council.science/current/>

*ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.*

*Latest Updates*

*Blogs*

**[Putting science on the agenda for post-crisis recovery](#)**

At the UNESCO Symposium on "Rebuilding Scientific Ecosystem in Ukraine," Vivi Stavrou, ISC Senior Science Officer and Executive Secretary of the ISC Committee for Freedom and Responsibility in Science (CFRS), stressed the necessity of a global framework to protect science during crises. She introduced the ISC's report, "Protecting Science in Times of Crisis," advocating for a coordinated and proactive response from the scientific community.

14.03.2024

**International Union of Immunological Societies (IUIS)**

<https://iuis.org/>

*News/Events [Selected]*  
*No new digest content identified.*

**IVAC** [to 16 Mar 2024]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

*Updates; Events*

*No new digest content identified.*

**IVI** [to 16 Mar 2024]

<http://www.ivi.int/>

*IVI News & Announcements*

**[Prof. Jan Holmgren, and Profs. Barney Graham / Jason McLellan to receive the 3rd IVI-SK bioscience Park MahnHoon Award](#)**

- Holmgren recognized for developing the world's first effective oral cholera vaccine
- Graham and McLellan recognized for pioneering work on the structure of viral spike proteins and the development of COVID-19 and RSV vaccines
- Award Ceremony to take place at Plaza Seoul Hotel on April 25

**Johns Hopkins Center for Health Security** [to 16 Mar 2024]

<https://centerforhealthsecurity.org/newsroom>

*Center News [Selected]*

*No new digest content identified.*

**MSF/Médecins Sans Frontières** [to 16 Mar 2024]

<http://www.msf.org/>

*Latest [Selected Announcements]*

*Chad*

**[Urgent action needed as hepatitis E spreads through Sudanese refugee camps in Chad](#)**

Press Release 15 Mar 2024

*Democratic Republic of Congo*

**[Massive humanitarian response needed to avoid health catastrophe in DRC](#)**

Interview 12 Mar 2024

*Nigeria*

**[Neglected humanitarian crisis escalates in northwest Nigeria](#)**

Press Release 11 Mar 2024

**National Academy of Medicine** - USA [to 16 Mar 2024]

<https://nam.edu/programs/>

*News [Selected]*

*No new digest content identified.*

**National Academy of Sciences** - USA [to 16 Mar 2024]

<https://www.nationalacademies.org/newsroom?>

*News*



*No new digest content identified.*

**National Vaccine Program Office** - U.S. HHS [to 16 Mar 2024]

<https://www.hhs.gov/vaccines/about/index.html>

*Upcoming Meetings/Latest Updates*

June 13-14, 2024

**NIH** [to 16 Mar 2024]

<http://www.nih.gov/>

*No new digest content identified.*

**PATH** [to 16 Mar 2024]

<https://www.path.org/media-center/>

*Newsroom*

*No new digest content identified.*

**Sabin Vaccine Institute** [to 16 Mar 2024]

<https://www.sabin.org/press/>

*Latest News & Press Releases*

*No new digest content identified.*

**UNAIDS** [to 16 Mar 2024]

<http://www.unaids.org/en>

*Selected Press Releases/Reports/Statements*

*Press statement*

**[UNAIDS urges scaling up of evidence-based services to address the transmission of HIV and viral hepatitis among people who use drugs](#)**

VIENNA/GENEVA, 14 March 2024

**UNICEF** [to 16 Mar 2024]

<https://www.unicef.org/media/press-releases>

*Latest press releases, news notes and statements*

*Press release 12 March 2024*

**[Global child deaths reach historic low in 2022 – UN report](#)**

GENEVA/NEW YORK/WASHINGTON, 13 March 2024 – The number of children who died before their fifth birthday has reached a historic low, dropping to 4.9 million in 2022, according to the latest estimates released today by the United Nations Inter-agency Group for Child Mortality Estimation (UN IGME). "Behind these numbers lie the stories of midwives...

**Unitaid** [to 16 Mar 2024]

<https://unitaid.org/>

*Featured News*

*No new digest content identified.*

**Vaccine Equity Cooperative [nee Initiative]** [to 16 Mar 2024]

<https://vaccineequitycooperative.org/news/>

*News*

*No new digest content identified.*

**Vaccination Acceptance & Demand Initiative [Sabin]** [to 16 Mar 2024]

<https://www.vaccineacceptance.org/>

*Announcements, Blog*

*No new digest content identified.*

**Vaccine Confidence Project** [to 16 Mar 2024]

<http://www.vaccineconfidence.org/>

*News, Research and Reports*

*No new digest content identified.*

**Vaccine Education Center – Children’s Hospital of Philadelphia** [to 16 Mar 2024]

<http://www.chop.edu/centers-programs/vaccine-education-center>

*News*

*No new digest content identified.*

**Wellcome Trust** [to 16 Mar 2024]

<https://wellcome.org/>

*News, Opinion, Reports*

*No new digest content identified.*

**The Wistar Institute** [to 16 Mar 2024]

<https://www.wistar.org/news/press-releases>

*Press Releases*

*No new digest content identified.*

**World Bank** [to 16 Mar 2024]

<http://www.worldbank.org/en/news/all>

*All News [Selected]*

**[Global child deaths reach historic low in 2022 – UN report](#)**

Despite progress, an estimated 4.9 million children died before their fifth birthday somewhere in the world, or 1 death every 6 seconds GENEVA/NEW YORK/WASHINGTON, 13 March 2024 – The number of children...

Date: March 13, 2024 Type: Press Release

**WFPHA: World Federation of Public Health Associations** [to 16 Mar 2024]

<https://www.wfpha.org/>

*Blog*

*No new digest content identified.*

**World Medical Association [WMA]** [to 16 Mar 2024]

<https://www.wma.net/news-press/press-releases/>

*Press Releases*

*No new digest content identified.*

**World Organisation for Animal Health** [to 16 Mar 2024]

<https://www.oie.int/en/>

*Press Releases, Statements*

*No new digest content identified.*

.....

**ARM [Alliance for Regenerative Medicine]** [to 16 Mar 2024]

<https://alliancerm.org/press-releases/>

*Selected Press Releases*

*No new digest content identified.*

**BIO** [to 16 Mar 2024]

<https://www.bio.org/press-releases>

*Press Releases*

[Biotechnology is a national security Imperative, says BIO CEO](#)

March 13, 2024

**DCVMN – Developing Country Vaccine Manufacturers Network** [to 16 Mar 2024]

<http://www.dcvmn.org/>

*News; Upcoming events*

*No new digest content identified.*

**ICBA – International Council of Biotechnology Associations** [to 16 Mar 2024]

<https://internationalbiotech.org/news/>

*News*

*No new digest content identified.*

**IFPMA** [to 16 Mar 2024]

<https://ifpma.org/>

*News*

*Statement* 11 Mar 2024

[Delivering equitable access in pandemics: Biopharmaceutical industry commitments](#)

In response to the threat of future global pandemics, the biopharmaceutical industry developed a set of commitments for equitable access to essential medical countermeasures in future pandemics.

**International Alliance of Patients' Organizations – IAPO** [to 16 Mar 2024]

<https://www.iapo.org.uk/news>

*Press and media [Selected]*

*No new digest announcements identified.*

## **International Generic and Biosimilar Medicines Association [IGBA]**

<https://www.igbamedicines.org/>

*News*

*No new digest announcements identified.*

## **PhRMA** [to 16 Mar 2024]

<http://www.phrma.org/>

*Press Releases*

*No new digest announcements identified.*



## ***Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements***

### **AstraZeneca**

*Press Releases* - No new digest announcements identified.

### **Bharat Biotech**

*Press Releases* - No new digest announcements identified.

### **BioCubaFarma** – Cuba

*Últimas Noticias* - No new digest announcements identified

### **Biological E**

*News* - No new digest announcements identified

### **BioNTech**

*Press Releases* - No new digest announcements identified

### **Boehringer**

*Press Releases* - No new digest announcements identified.

### **CanSinoBIO**

*News* - Website not responding at inquiry

### **CIGB**

*Latest News* - No new digest announcements identified.

### **Cinnagen**

*Recent News* - No new digest announcements identified.

### **Clover Biopharmaceuticals** - China

*News* - No new digest announcements identified.

### **Curevac [Bayer Ag – Germany]**

*News* - No new digest announcements identified

### **Gamaleya National Center/Sputnik**

*Latest News and Events* - No new digest announcements identified

<https://sputnikvaccine.com/> - No new digest announcements identified

## **GSK**

[Press releases for media](#) - No new digest announcements identified

## **IMBCAMS, China**

[Home](#) - Website not responding at inquiry.

## **Janssen/JNJ**

[Press Releases](#) - No new digest announcements identified

## **Merck**

[News releases](#)

[Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus \(HPV\) Vaccine and Single-Dose Regimen for GARDASIL®9](#)

March 13, 2024

*Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers*

## **Moderna**

[Press Releases](#)

March 15, 2024

[Long COVID Awareness Day: Amplifying the Patient Voice](#)

## **Nanogen**

[News](#) - No new digest announcements identified

## **Novartis**

[News](#) - No new digest announcements identified.

## **Novavax**

[Press Releases](#)

Mar 11, 2024

*Statement COVID-19*

[Canada National Advisory Committee Publishes Recommendation for Use of Novavax's Nuvaxovid™ XBB.1.5 COVID-19 Vaccine](#)

## **Pfizer**

[Recent Press Releases](#)

03.13.2024 Vaccines

[European Commission Approves Pfizer's PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease](#)

## **R-Pharm**

<https://rpharm-us.com/index.php>

[No news or media page identified]

## **Sanofi Pasteur**

[Press Releases](#) - No new digest announcements identified

## **Serum Institute of India**

[NEWS & ANNOUNCEMENTS](#) - No new digest announcements identified

## **Sinopharm/WIBPBIBP**

News - No new digest announcements identified [English translation function not operating]

## **Sinovac**

Press Releases - No new digest announcements identified

## **SK Biosciences**

Press Releases

### **[SK bioscience and IVI Announce 2024 Park MahnHoon Award Winners](#)**

- Prof. Holmgren recognized for developing the world's first effective oral cholera vaccine...  
2024.03.14

## **Takeda**

Newsroom - No new digest announcements identified.

## **Valneva**

Press Releases - No new digest announcements identified.

## **Vector State Research Centre of Virology and Biotechnology**

Home - Website not responding [404 error]

## **WestVac Biopharma**

Media - No new digest announcements identified.

## **Zhifei Longcom, China**

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

Website [No News/Announcements page identified]

.....  
.....

### ***Contents [click to move among sections]***

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....  
.....

### ***Journal Watch***

*Vaccines and Global Health: The Week in Review* continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)

### **AJOB Empirical Bioethics**

Volume 15, 2023 Issue 1

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

### **AMA Journal of Ethics**

Volume 26, Number 3: E195-273 Mar 2024

<https://journalofethics.ama-assn.org/issue/critical-pedagogies-health-professions-education>

#### ***Psychiatric Inpatient Environmental Architecture***

Inpatient psychiatric units designed to reduce patients' risk of harm to self or others can compromise patients' comfort. Some environmental modifications prioritize safety by limiting patients' access to personal items. This set of clinical phenomena is not ethically neutral and should prompt us to carefully consider when and how patients' experiences of their care environments undermine therapeutic goals of their hospitalizations. This theme issue investigates which criteria we should use to assess and evaluate patients' risk of harm to self or others and which values we should rely upon to guide which iatrogenic harm risks we accept as products or byproducts of clinical and organizational environmental designs.

[Reviewed earlier]

### **American Journal of Human Genetics**

Mar 07, 2024 Volume 111 Issue 3 p403-620

<https://www.cell.com/ajhg/current>

#### **This Month in The Journal**

Alyson B. Barnes, Kylee L. Spencer, Sara B. Cullinan

In Our DNA SC, a program developed to ensure that all individuals in South Carolina have access to genomic screening, recently reached an interim milestone of 20,000 participants. Over 14 months, 20,478 participants enrolled, and 13,643 samples were collected through clinical appointments, 108 community events, or at-home sample collection. A total of 1.3% of participants were found to have a pathogenic or likely pathogenic variant for a CDC Tier 1 condition; 77.4% of those agreed to genetic counseling and 80.2% completed counseling.

### **American Journal of Infection Control**

March 2024 Volume 52 Issue 3 p261-380

<http://www.ajicjournal.org/current>

[Reviewed earlier]

### **American Journal of Preventive Medicine**

March 2024 Volume 66 Issue 3 p389-572

<https://www.ajpmonline.org/current>

[Reviewed earlier]

### **American Journal of Public Health**

March 2024 114(3)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

## **American Journal of Tropical Medicine and Hygiene**

Volume 110 (2024): Issue 2 (Feb 2024)

<https://www.ajtmh.org/view/journals/tpmd/110/2/tpmd.110.issue-2.xml>

[Reviewed earlier]

## **Annals of Internal Medicine**

February 2024 Volume 177, Issue 2

<https://www.acpjournals.org/toc/aim/current>

[Reviewed earlier]

## **Artificial Intelligence – An International Journal**

Volume 328 March 2024

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/328/suppl/C>

[New issue; No digest content identified]

## **BMC Cost Effectiveness and Resource Allocation**

<http://resource-allocation.biomedcentral.com/>

(Accessed 16 Mar 2024)

[No new digest content identified]

## **BMC Health Services Research**

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 16 Mar 2024)

[No new digest content identified]

## **BMC Infectious Diseases**

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 16 Mar 2024)

### **[Circulating vaccine derived polio virus type 2 outbreak and response in Yemen, 2021–2022, a retrospective descriptive analysis](#)**

*The outbreaks of circulating Vaccine Derived Polio Viruses (cVDPVs) have emerged as a m...*

Authors: Mutahar Ahmed Al-Qassimi, Mohammed Al Amad, Ahmed Al-Dar, Ehab Al Sakaf, Ahmed Al Hadad and Yahia Ahmed Raja'a

Citation: BMC Infectious Diseases 2024 24:321

Content type: Research Published on: 15 March 2024

### **[Predictors of COVID-19 vaccine uptake: an online three-wave survey study of US adults](#)**

*To effectively promote vaccine uptake, it is important to understand which people are most and least inclined to be vaccinated and why. In this study, we examined predictors of COVID-19 vaccine uptake and reas...*

Authors: Alistair Thorpe, Angela Fagerlin, Frank A. Drews, Holly Shoemaker, Federica S. Brecha and Laura D. Scherer

Citation: BMC Infectious Diseases 2024 24:304

Content type: Research Published on: 12 March 2024



## **BMC Medical Ethics**

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 16 Mar 2024)

### **[Comprehension of informed consent and voluntary participation in registration cohorts for phase IIb HIV vaccine trial in Dar Es Salaam, Tanzania: a qualitative descriptive study](#)**

Authors: Masunga K. Iseselo and Edith A. M. Tarimo

## **BMC Medicine**

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 16 Mar 2024)

### **[Risk of encephalitis and meningitis after COVID-19 vaccination in South Korea: a self-controlled case series analysis](#)**

*Several neurological manifestations shortly after a receipt of coronavirus infectious disease 2019 (COVID-19) vaccine have been described in the recent case reports. Among those, we sought to evaluate the risk...*

Authors: Ju Hwan Kim, Dongwon Yoon, Hwa Yeon Ko, Kyungyeon Jung, Jun-Sang Sunwoo, Won Chul Shin, Jung-Ick Byun and Ju-Young Shin

Citation: BMC Medicine 2024 22:123

Content type: Research article Published on: 14 March 2024

### **[Malaria vaccination: hurdles to reach high-risk children](#)**

*Ensuring that malaria vaccines deliver maximum public health impact is non-trivial. Drawing on current research, this article examines hurdles that malaria immunization may face to reach high-risk children and...*

Authors: Floriano Amimo

Citation: BMC Medicine 2024 22:111

Content type: Opinion Published on: 13 March 2024

## **BMC Pregnancy and Childbirth**

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 16 Mar 2024)

[No new digest content identified]

## **BMC Public Health**

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 16 Mar 2024)

### **[Trust in federal COVID-19 vaccine oversight and parents' willingness to vaccinate their children against COVID-19: a cross-sectional study](#)**

*Over half of the youth population in the United States, aged 6 months to 17 years, have not received the Coronavirus Disease 2019 (COVID-19) vaccine. Given parents' central role in vaccinating their children, ...*

Authors: Hyunmin Yu, José A. Bauermeister, Ufuoma Oyiborhoro, Subhash Aryal, Terri H. Lipman, Andy S. L. Tan, Karen Glanz, Antonia M. Villarruel and Stephen Bonett

Citation: BMC Public Health 2024 24:830

Content type: Research Published on: 16 March 2024

**Rates and determinants of Rotavirus vaccine uptake among children in Italy: a cross-sectional study within the 2022 OBVIOUS\* project**

*The World Health Organization defines rotavirus as among the most severe causes of viral gastroenteritis affecting children under 5 year old. Italy and other European countries do not release disaggregated dat...*

Authors: Giusy La Fauci, Giorgia Soldà, Zeno Di Valerio, Aurelia Salussolia, Marco Montalti, Francesca Scognamiglio, Angelo Capodici, Maria Pia Fantini, Heidi J. Larson, Julie Leask, Davide Gori and Jacopo Lenzi

Citation: BMC Public Health 2024 24:770

Content type: Research Published on: 12 March 2024

**BMC Research Notes**

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 16 Mar 2024)

[No new digest content identified]

**BMJ Evidence-Based Medicine**

February 2024 - Volume 29 - 1

<https://ebm.bmj.com/content/29/1>

[Reviewed earlier]

**BMJ Global Health**

March 2024 - Volume 9 - 3

<https://gh.bmj.com/content/9/3>

[Reviewed earlier]

**Bulletin of the Atomic Scientists**

March 2024

<https://thebulletin.org/magazine/2024-03/>

[Reviewed earlier]

**Bulletin of the World Health Organization**

Volume 102(3); 2024 Mar 1

<https://www.ncbi.nlm.nih.gov/pmc/issues/456622/>

[Reviewed earlier]

**Cell**

Feb 29, 2024 Volume 187 Issue 5 p1017-1314

<https://www.cell.com/cell/current>

[Reviewed earlier]

**Child Care, Health and Development**

Volume 50, Issue 2 March 2024

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

### **Clinical Pharmacology & Therapeutics**

Volume 115, Issue 3 Pages: 375-626 March 2024

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

#### ***Subcutaneous Biologics: Clinical Pharmacology and Drug Development***

[Reviewed earlier]

### **Clinical Therapeutics**

February 2024 Volume 46 Issue 2 p85-184

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

### **Clinical Trials**

Volume 21 Issue 1, February 2024

<https://journals.sagepub.com/toc/ctja/21/1>

[Reviewed earlier]

### **Conflict and Health**

<http://www.conflictandhealth.com/>

[Accessed 16 Mar 2024]

#### **[Echoes of conflict: the enduring mental health struggle of Gaza's healthcare workers](#)**

Authors: Muna Abed Alah

Content type: Comment 14 March 2024

### **Contemporary Clinical Trials**

Volume 138 March 2024

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/1387/suppl/C>

[New issue; No digest content identified]

### **The CRISPR Journal**

Volume 7, Issue 1 / February 2024

<https://www.liebertpub.com/toc/crispr/7/1>

[Reviewed earlier]

### **Current Genetic Medicine Reports**

Volume 11, issue 1-2, June 2023

<https://link.springer.com/journal/40142/volumes-and-issues/11-1>

[Reviewed earlier]

### **Current Medical Research and Opinion**

Volume 40, Issue 3 2024

<https://www.tandfonline.com/toc/icmo20/current>

Article

**[Association between COVID-19 vaccines and development of chronic morbidities: a cross-sectional study in the Jordanian population](#)**

Mai I. AL-Hawamdeh, Rana Abu-Huwaij, Thabit A. Astiti, Ahmed K. Al-Debe'e, Omar J. Abazeed & Mohammed A. Raees

Pages: 537-543

Published online: 16 Jan 2024

**Current Opinion in Infectious Diseases**

April 2024 - Volume 37 - Issue 2

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

**Current Protocols in Human Genetics**

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 16 Mar 2024]

[No new digest content identified]

**Developing World Bioethics**

Volume 24, Issue 1 Pages: 1-48 March 2024

<https://onlinelibrary.wiley.com/toc/14718847/current>

***Access to Essential Medicines for Global Health and the Human Right to Health***

[Reviewed earlier]

**Development in Practice**

Volume 34, Issue 1, 2024

<http://www.tandfonline.com/toc/cdip20/current>

[Reviewed earlier]

**Development Policy Review**

Volume 42, Issue 2 March 2024

<https://onlinelibrary.wiley.com/toc/14677679/current>

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

**Disaster Medicine and Public Health Preparedness**

Volume 18 - 2024

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

**Disasters**

Volume 48, Issue 1 January 2024

<https://onlinelibrary.wiley.com/toc/14677717/2024/48/1>

[Reviewed earlier]

### **EMBO Reports**

Volume 25 Issue 2 13 February 2024

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

### **Emerging Infectious Diseases**

Volume 30, Number 2—February 2024

<http://wwwnc.cdc.gov/eid/>

[New issue; No digest content identified]

### **Epidemics**

Volume 46 March 2024

<https://www.sciencedirect.com/journal/epidemics/vol/46/suppl/C>

[New issue; No digest content identified]

### **Epidemiology and Infection**

Volume 152 - 2024

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

### **Ethics & Human Research**

Volume 46, Issue 2 Pages: 1-35 March–April 2024

<https://onlinelibrary.wiley.com/toc/25782363/current>

***Indigenous data sovereignty :: Returning clinically relevant results***

[Reviewed earlier]

### **Ethics & International Affairs**

Volume 37 - Issue 4 - Winter 2023

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>

[Reviewed earlier]

### **Ethics, Medicine and Public Health**

Volume 31 (December 2023)

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/31/suppl/C>

[Reviewed earlier]

### **The European Journal of Public Health**

Volume 34, Issue 1, February 2024

<https://academic.oup.com/eurpub/issue/34/1>

*Viewpoints*

**[Learning policy lessons from the pandemic: the UK's COVID Inquiry](#)**

Martin McKee

European Journal of Public Health, Volume 34, Issue 1, February 2024, Pages 5–6,

<https://doi.org/10.1093/eurpub/ckad222>

## *Vaccination*

### **[An analysis of COVID-19 vaccination campaign in Ukraine](#)**

Tetiana Vasylivna Mamontova

European Journal of Public Health, Volume 34, Issue 1, February 2024, Pages 156–162,  
<https://doi.org/10.1093/eurpub/ckad201>

### **[Factors associated with vaccine adherence among an underserved population: the adult Travellers in Nouvelle-Aquitaine, France](#)**

Sahar Haidar and others

European Journal of Public Health, Volume 34, Issue 1, February 2024, Pages 163–169,  
<https://doi.org/10.1093/eurpub/ckad203>

### **[Cost of illness of the vaccine-preventable diseases influenza, herpes zoster and pneumococcal disease in France](#)**

Lauren Brown and others

European Journal of Public Health, Volume 34, Issue 1, February 2024, Pages 170–175,  
<https://doi.org/10.1093/eurpub/ckad212>

## **Expert Review of Vaccines**

Vol 23 (1) 2023

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

## **Foreign Affairs**

March/April 2024 Volume 103, Number 2

<https://www.foreignaffairs.com/issues/2023/103/2>

[Reviewed earlier]

## **Forum for Development Studies**

Volume 51, 2023 - Issue 1

<http://www.tandfonline.com/toc/sfds20/current>

[Reviewed earlier]

## **Genetics in Medicines**

Volume 26, Issue 3 March 2024

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/26/issue/3>

[Reviewed earlier]

## **Genome Medicine**

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 16 Mar 2024]

[No new digest content identified]

## **Global Health Action**

Volume 17, Issue 1 (2024)

<https://www.tandfonline.com/toc/zgha20/current?nav=toclist>

[Reviewed earlier]

### **Global Health: Science and Practice (GHSP)**

Vol. 12, No. 1 February 28, 2024

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

### **Global Legal Monitor & Legal Reports – Library of Congress/USA**

<https://www.loc.gov/collections/global-legal-monitor/>

[https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date\\_desc](https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc)

[Accessed 16 Mar 2024]

[No new digest content identified]

### **Global Public Health**

Volume 19, Issue 1 (2024)

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

### **Globalization and Health**

<http://www.globalizationandhealth.com/>

[Accessed 16 Mar 2024]

[No new digest content identified]

### **Health and Human Rights**

Volume 25, Issue 2, December 2023

<https://www.hhrjournal.org/volume-25-issue-2-december-2023/>

***Special Section: Economic Inequality and the Right to Health***

[Reviewed earlier]

### **Health Economics, Policy and Law**

Volume 19 - Issue 1 - January 2024

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

### **Health Policy and Planning**

Volume 39, Issue 1, January 2024

<https://academic.oup.com/heapol/issue/39/1>

[Reviewed earlier]

### **Health Research Policy and Systems**

<http://www.health-policy-systems.com/content>

[Accessed 16 Mar 2024]

[No new digest content identified]

## **Human Gene Therapy**

Volume 35, Issue 3-4 / February 2024

<https://www.liebertpub.com/toc/hum/35/3-4>

[Reviewed earlier]

## **Humanitarian Practice Network**

<https://odihpn.org/>

*Featured Publications*

[No new digest content identified]

## **Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)

Volume 19, Issue 3, 2023

<https://www.tandfonline.com/toc/khvi20/19/3?nav=tocList>

[Reviewed earlier]

## **Immunity**

Feb 13, 2024 Volume 57 Issue 2 p193-400

<https://www.cell.com/immunity/current>

[Reviewed earlier]

## **Infectious Agents and Cancer**

<http://www.infectagentscancer.com/>

[Accessed 16 Mar 2024]

[No new digest content identified]

## **Infectious Diseases of Poverty**

<http://www.idpjournals.com/content>

[Accessed 16 Mar 2024]

### **[Advancing the National Immunization Program in an era of achieving universal vaccine coverage in China and beyond](#)**

*Immunization is a cornerstone of public health. Despite great success, China's National Immunization Program (NIP) faces challenges, such as the integration of several World Health Organization-recommended vac...*

Authors: Shu Chen, Lance E. Rodewald, Anna Heng Du and Shenglan Tang

Citation: Infectious Diseases of Poverty 2024 13:25

Content type: Editorial Published on: 13 March 2024

## **International Health**

Volume 16, Issue 2, March 2024

<https://academic.oup.com/inthealth/issue/16/2>

[Reviewed earlier]



### **International Human Rights Law Review**

Volume 12 (2023): Issue 2 (Dec 2023)

<https://brill.com/view/journals/hrlr/12/2/hrlr.12.issue-2.xml>

*Table of Contents*

[Reviewed earlier]

### **International Journal of Community Medicine and Public Health**

Vol. 11 No. 3 (2024): March 2024

<https://www.ijcmph.com/index.php/ijcmph/issue/view/110>

[Reviewed earlier]

### **International Journal of Epidemiology**

Volume 52, Issue 6, December 2023

<https://academic.oup.com/ije/issue>

[Reviewed earlier]

### **International Journal of Human Rights in Healthcare**

Volume 17 Issue 1 2024

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/17/iss/1>

*Table of contents*

[Reviewed earlier]

### **JAMA**

March 12, 2024, Vol 331, No. 10, Pages 813-894

<https://jamanetwork.com/journals/jama/currentissue>

[New issue; No digest content identified]

### **JAMA Health Forum**

March 2024, Vol 5, No. 3

<https://jamanetwork.com/journals/jama-health-forum/issue>

[Reviewed earlier]

### **JAMA Pediatrics**

March 2024, Vol 178, No. 3, Pages 211-322

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

### **JBIC Evidence Synthesis**

February 2024 - Volume 22 - Issue 2

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

### **Journal of Adolescent Health**

March 2024 Volume 74 Issue 3 p395-628

<https://www.jahonline.org/current>

[Reviewed earlier]

### **Journal of Artificial Intelligence Research**

Vol. 79 (2024)

<https://www.jair.org/index.php/jair>

*Contents*

[Reviewed earlier]

### **Journal of Community Health**

Volume 49, Issue 2 April 2024

<https://link.springer.com/journal/10900/volumes-and-issues/49-2>

*Articles*

#### **[Compulsory Vaccination Coverage in 12 Sub-Saharan African Countries Two Years Following the COVID-19 Pandemic](#)**

Ramy Mohamed Ghazy, Assem Gebreal, Noha Fadl

Original Paper 30 August 2023 Pages: 193 - 206

### **Journal of Current Medical Research and Opinion**

*...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.*

Vol. 7 No. 01 (2024), January 2, 2024 , Page 1988-1996

<https://www.cmro.in/index.php/jcmro/issue/view/75>

[New issue; No digest content identified]

### **Journal of Development Economics**

Volume 167 March 2024

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/167/suppl/C>

[Reviewed earlier]

### **Journal of Empirical Research on Human Research Ethics**

Volume 18 Issue 5, December 2023

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

### **Journal of Epidemiology & Community Health**

February 2024 - Volume 78 - 2

<https://jech.bmj.com/content/78/2>

[Reviewed earlier]

### **Journal of Evidence-Based Medicine**

Volume 16, Issue 4 Pages: 415-580 December 2023

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

### **Journal of Global Ethics**

Volume 19, Issue 3 (2023)

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

### **Journal of Health Care for the Poor and Underserved (JHCPU)**

Volume 35, Number 1, February 2024

<https://muse.jhu.edu/issue/52063>

*Table of Contents*

[Reviewed earlier]

### **Journal of Immigrant and Minority Health**

Volume 26, Issue 2 April 2024

<https://link.springer.com/journal/10903/volumes-and-issues/26-2>

[New issue; No digest content identified]

### **Journal of Immigrant & Refugee Studies**

Volume 22, 2024 \_ Issue 1

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

### **Journal of Infectious Diseases**

Volume 229, Issue 3, 15 March 2024

<https://academic.oup.com/jid/issue/229/3>

*Global Health*

#### **[Impact of Supplementary Immunization Activities using Novel Oral Polio Vaccine Type 2 during a Large outbreak of Circulating Vaccine-Derived Poliovirus in Nigeria](#)**

Arend Voorman and others

The Journal of Infectious Diseases, Volume 229, Issue 3, 15 March 2024, Pages 805–812,

<https://doi.org/10.1093/infdis/jiad222>

Using a bayesian time-series susceptible-infectious-recovered model, we evaluated novel oral poliovirus vaccine type 2 (OPV2) in Nigeria and found the impact on disease transmission comparable to that previously achieved with monovalent OPV2.

### **Journal of International Development**

Volume 36, Issue 2 Pages: 773-1592 March 2024

<https://onlinelibrary.wiley.com/toc/10991328/current>

[New issue; No digest content identified]

### **Journal of Medical Ethics**

March 2024 - Volume 50 - 3

<http://jme.bmj.com/content/current>

[Reviewed earlier]

**Journal of Patient-Centered Research and Reviews**

Volume 10, Issue 4 (2023)

<https://institutionalrepository.aah.org/jpcrr/>

[Reviewed earlier]

**The Journal of Pediatrics**

Volume 266 March 2024

<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/266/suppl/C>

[Reviewed earlier]

**Journal of Pharmaceutical Policy and Practice**

Volume 17, Issue 1 (2024) Issue 1

<https://www.tandfonline.com/toc/jppp20/17/1>

[Reviewed earlier]

**Journal of Public Health Management & Practice**

January/February 2024 - Volume 30 - Issue 1

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

**Journal of Public Health Policy**

Volume 45, issue 1, March 2024

<https://link.springer.com/journal/41271/volumes-and-issues/45-1>

[New issue; No digest content identified]

**Journal of the Royal Society – Interface**

March 2024 Volume 21 Issue 212

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

**Journal of Travel Medicine**

Volume 31, Issue 2, March 2024

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

**Journal of Virology**

Volume 98 • Number 2 • February 2024

<http://jvi.asm.org/content/current>

[Reviewed earlier]

**The Lancet**

Mar 16, 2024 Volume 403 Number 10431 p997-1108

<https://www.thelancet.com/journals/lancet/issue/current>

[New issue; No digest content identified]

### **The Lancet Child & Adolescent Health**

Mar 2024 Volume 8 Number 3 p175-244, e2-e5  
<https://www.thelancet.com/journals/lanchi/issue/current>  
[Reviewed earlier]

### **Lancet Digital Health**

Mar 2024 Volume 6 Number 3 e145-e229  
<https://www.thelancet.com/journals/landig/issue/current>  
[Reviewed earlier]

### **Lancet Global Health**

Mar 2024 Volume 12 Number 3 e341-e529  
<https://www.thelancet.com/journals/langlo/issue/current>  
[Reviewed earlier]

### **Lancet Infectious Diseases**

Mar 2024 Volume 24 Number 3 p217-328, e137-e206  
<https://www.thelancet.com/journals/laninf/issue/current>  
[Reviewed earlier]

### **Lancet Public Health**

Mar 2024 Volume 9 Number 3 e147-e206  
<https://www.thelancet.com/journals/lanpub/issue/current>  
[Reviewed earlier]

### **Lancet Respiratory Medicine**

Mar 2024 Volume 12 Number 3 p181-254, e7-e12  
<https://www.thelancet.com/journals/lanres/issue/current>  
[Reviewed earlier]

### **Maternal and Child Health Journal**

Volume 27, issue 12, December 2023  
<https://link.springer.com/journal/10995/volumes-and-issues/27-12>  
[Reviewed earlier]

### **Medical Decision Making (MDM)**

Volume 44 Issue 2, February 2024  
<http://mdm.sagepub.com/content/current>  
[Reviewed earlier]

### **The Milbank Quarterly**

*A Multidisciplinary Journal of Population Health and Health Policy*

Volume 102, Issue 1 Pages: 1-269 March 2024

<https://onlinelibrary.wiley.com/toc/14680009/current>

*Perspective*

### **[Prescription for Cash? Cash Support to Low-Income Families in Maternal and Pediatric Health Care Settings](#)**

MARGARET MCCONNELL, SUMIT AGARWAL, ERIKA HANSON, ERIN MCCRADY, MARGARET G. PARKER, KIRA BONA

Pages: 64-82

First Published: 22 November 2023

*Policy Points*

:: Pregnancy and childhood are periods of heightened economic vulnerability, but current policies for addressing health-related social needs, including screening and referral programs, may be insufficient because of persistent gaps, incomplete follow-up, administrative burden, and limited take-up.

:: To bridge gaps in the social safety net, direct provision of cash transfers to low-income families experiencing health challenges during pregnancy, infancy, and early childhood could provide families with the flexibility and support to enable caregiving, increase access to health care, and improve health outcomes.

### **Molecular Therapy**

Mar 06, 2024 Volume 32 Issue 3 p563-856

<https://www.cell.com/molecular-therapy/current>

[Reviewed earlier]

### **Nature**

Volume 627 Issue 8003, 14 March 2024

<https://www.nature.com/nature/volumes/627/issues/8002>

[New issue; No digest content identified]

### **Nature Biotechnology**

Volume 42 Issue 3, March 2024

<https://www.nature.com/nbt/volumes/42/issues/3>

*Article* 24 Apr 2023

### **[A microneedle vaccine printer for thermostable COVID-19 mRNA vaccines](#)**

Automated fabrication of microneedle patch mRNA vaccines for COVID-19 may improve vaccine access.

Aurélien vander Straeten, Morteza Sarmadi, Ana Jaklenec

### **Nature Communications**

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 16 Mar 2024)

[No new digest content identified]

### **Nature Genetics**

Volume 56 Issue 3, March 2024

<https://www.nature.com/ng/volumes/56/issues/3>

[New issue; No digest content identified]

### **Nature Human Behaviour**

Volume 8 Issue 2, February 2024

<https://www.nature.com/nathumbehav/volumes/8/issues/2>

[Reviewed earlier]

### **Nature Medicine**

Volume 30 Issue 2, February 2024

<https://www.nature.com/nm/volumes/30/issues/2>

[Reviewed earlier]

### **Nature Reviews Drug Discovery**

Volume 23 Issue 3, March 2024

<https://www.nature.com/nrd/volumes/23/issues/3>

[Reviewed earlier]

### **Nature Reviews Genetics**

Volume 25 Issue 3, March 2024

<https://www.nature.com/nrg/volumes/25/issues/3>

[Reviewed earlier]

### **Nature Reviews Immunology**

Volume 24 Issue 3, March 2024

<https://www.nature.com/nri/volumes/24/issues/3>

[Reviewed earlier]

### **New England Journal of Medicine**

March 14, 2024 Vol. 390 No. 11

<https://www.nejm.org/toc/nejm/medical-journal>

[New issue; No digest content identified]

### **njp Vaccines**

<https://www.nature.com/npjvaccines/>

[Accessed 16 Mar 2024]

[No new digest content identified]

### **Pediatrics**

Volume 153, Issue 3 March 2024

<https://publications.aap.org/pediatrics/issue/153/3>

[Reviewed earlier]

### **PharmacoEconomics**

Volume 42, Issue 3 March 2024

<https://link.springer.com/journal/40273/volumes-and-issues/42-3>

[Reviewed earlier]

### **PLoS Biology**

<https://journals.plos.org/plosbiology/>

(Accessed 16 Mar 2024)

[No new digest content identified]

### **PLoS Genetics**

<https://journals.plos.org/plosgenetics/>

(Accessed 16 Mar 2024)

[No new digest content identified]

### **PLoS Global Public Health**

[https://journals.plos.org/globalpublichealth/search?sortOrder=DATE\\_NEWEST\\_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60](https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60)

(Accessed 16 Mar 2024)

#### **[Factors associated with Covid-19 vaccine acceptance among persons with disabilities: A cross-sectional study in Ghana](#)**

Godfred Atta-Osei, Enoch Acheampong, Daniel Gyaase, Rebecca Tawiah, Theresah Ivy Gyaase, Richard Adade, Douglas Fofie, Isaac Owusu, Wisdom Kwadwo Mprah

Research Article | published 14 Mar 2024 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0002822>

#### **[Feasibility of wastewater-based detection of emergent pandemics through a global network of airports](#)**

Shihui Jin, Borame L. Dickens, Kai Yee Toh, David Chien Boon Lye, Vernon J. Lee, Alex R. Cook

Research Article | published 13 Mar 2024 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0003010>

### **PLoS Medicine**

<http://www.plosmedicine.org/>

(Accessed 16 Mar 2024)

[No new digest content identified]

### **PLoS Neglected Tropical Diseases**

<http://www.plosntds.org/>

(Accessed 16 Mar 2024)

[No new digest content identified]

### **PLoS One**

<http://www.plosone.org/>

[Accessed 16 Mar 2024]

[No new digest content identified]



## **PLoS Pathogens**

<http://journals.plos.org/plospathogens/>

[Accessed 16 Mar 2024]

[No new digest content identified]

## **PNAS - Proceedings of the National Academy of Sciences of the United States**

March 12, 2024 vol. 121 no. 11

<https://www.pnas.org/toc/pnas/121/11>

*Special Feature*

### **[Nanoparticles for RNA Therapeutics](#)**

*Introduction* March 4, 2024

#### **[RNA delivery systems](#)**

Sangeeta N. Bhatia and James E. Dahlman

Between December 2020 and December 2021, COVID-19 vaccines prevented over 14 million deaths (1). Two of these vaccines were lipid nanoparticles (LNPs) formulated to carry mRNA. Other LNP-RNA drugs, including those that edit (2) or silence (3–8) genes in vivo, have generated excellent data in patients. At first glance, these results underscore an exciting concept: RNA therapies have arrived.

Yet, this concept comes with a big asterisk: If an RNA drug cannot enter the right target cell, it will not work. Since RNAs are large and anionic, they cannot efficiently cross the cell bilayer on their own and therefore usually require a drug delivery system (9). One bright spot in the field is clinical delivery to hepatocytes, which has already been reported (2–8). In a leading example, Alnylam Pharmaceuticals earned five FDA approvals between 2018 and 2023; ongoing clinical trials suggest that liver programs from other companies are also going well.

These data strongly indicate that many clinical programs could result from improving liver targeting or unlocking a single new (i.e., non-liver) cell type. As a result, academic and company labs across the world work on improving delivery. In this Special Feature, a subset of these efforts is shared via four perspectives and seven research articles. Highlighting the diverse approaches scientists are taking to improve delivery, these articles span topics as disparate as protein engineering, polyanion design, DNA barcoding, and self-reporting RNA nanosystems. The variety of scientific approaches described here is consistent with the fact that drug delivery is a complex, interdisciplinary process...

## **PNAS Nexus**

Volume 3, Issue 2, February 2024

<https://academic.oup.com/pnasnexus/issue/3/2>

[Reviewed earlier]

## **Prehospital & Disaster Medicine**

Volume 39 - Issue 1 - February 2024

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

## **Preventive Medicine**

Volume 180 March 2024

<https://www.sciencedirect.com/journal/preventive-medicine/vol/180/suppl/C>

[Reviewed earlier]

## **Proceedings of the Royal Society B**

13 March 2024 Volume 291 Issue 2018

<https://royalsocietypublishing.org/toc/rspb/current>

[Reviewed earlier]

## **Public Health**

Volume 227 Pages e1-e4, 1-298 (February 2024)

<https://www.sciencedirect.com/journal/public-health/vol/227/suppl/C>

[Reviewed earlier]

## **Public Health Ethics**

Volume 16, Issue 3, November 2023

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

## **Public Health Genomics**

2024, Vol. 27, No. 1

<https://karger.com/phg/issue/27/1>

*Perspectives*

### **[Next-Generation Public Health Genomics: A Call to Assess the Equitable Implementation, Population Health Impact, and Sustainability of Precision Public Health Applications](#)**

Megan C. Roberts; Caitlin G. Allen

The field of Public Health Genomics recently celebrated its twenty-fifth anniversary [1]. Defined by the CDC as responsible and effective translation of genome-based knowledge and technologies for the benefit of population health, public health genomics applications have expanded beyond newborn screening to other applications poised to improve public health [2, 3]. Yet despite the promise and potential for public health genomics, the population health impact and sustainability of public health genomics applications has yet to be fully measured and achieved. Further access to public health genomics applications has been lower among underrepresented racial and ethnic communities, rural communities, and groups with lower education and income [2], deepening concerns that the field could exacerbate rather than redress health inequities [4, 5]. As we enter the next generation of public health genomics, we must shift our focus from not only understanding the collection of genetic risk information and related needs, but also the real-world use of this precision information and its impact on population health outcomes and health equity over time...

## **Public Health Reports**

Volume 139 Issue 2, March/April 2024

<https://journals.sagepub.com/toc/phrg/139/2>

*Case report*

### **[School-Located Vaccine Clinics: An Effective Strategy for Expanding Access to COVID-19 Vaccines in Los Angeles County](#)**

Cassandra Fink Biederman, MPH

First published online December 18, 2023

## **Lessons Learned From Adolescent COVID-19 Vaccine Administration in Medically Underserved Communities**

Sue C. Lin PhD, MS, Julie Fife Donney PhD, MPH, Lydie A. Lebrun-Harris PhD, MPH  
Research article First published January 19, 2024pp. 241–251

### **Qualitative Health Research**

Volume 34 Issue 4, March 2024

<https://journals.sagepub.com/toc/QHR/current>

[Reviewed earlier]

### **Research Ethics**

Volume 20 Issue 1, January 2024

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

### **Reproductive Health**

<http://www.reproductive-health-journal.com/content>

[Accessed 16 Mar 2024]

[No new digest content identified]

### **Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)**

<https://www.paho.org/journal/en>

[No new digest content identified]

### **Risk Analysis**

Volume 44, Issue 3 Pages: 509-737 March 2024

<https://onlinelibrary.wiley.com/toc/15396924/current>

[Reviewed earlier]

### **Risk Management and Healthcare Policy**

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 16 Mar 2024]

[Reviewed earlier]

### **Science**

Volume 383| Issue 6688| 15 Mar 2024

<https://www.science.org/toc/science/current>

[New issue; No digest content identified]

### **Science and Engineering Ethics**

Volume 30, Issue 1 February 2024

<https://link.springer.com/journal/11948/volumes-and-issues/30-1>

[Reviewed earlier]

### **Science Translational Medicine**

Volume 16| Issue 738| 13 Mar 2024

<https://www.science.org/toc/stm/current>

[New issue; No digest content identified]

### **Scientific Reports**

<https://www.nature.com/srep/articles?type=article>

[Accessed 16 Mar 2024]

[No new digest content identified]

### **Social Science & Medicine**

Volume 343 February 2024

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/343/suppl/C>

[Reviewed earlier]

### **Systematic Reviews**

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 16 Mar 2024]

[No new digest content identified]

### **Theoretical Medicine and Bioethics**

Volume 45, Issue 1 February 2024

<https://link.springer.com/journal/11017/volumes-and-issues/45-1>

[Reviewed earlier]

### **Travel Medicine and Infectious Diseases**

Volume 57 January–February 2024

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/57/suppl/C>

[Reviewed earlier]

### **Tropical Medicine & International Health**

Volume 29, Issue 3 Pages: i-iv, 161-255 March 2024

<https://onlinelibrary.wiley.com/toc/13653156/current>

*Reviews*

[\*\*Risk factors associated with severe dengue in Latin America: A systematic review and meta-analysis\*\*](#)

Victoria Cruz Paraná, Caroline Alves Feitosa, Greice Carolina Santos da Silva, Luana Leandro Gois, Luciane Amorim Santos

Pages: 173-191

First Published: 23 January 2024

### **Vaccine**

Volume 42, Issue 7 Pages 1407-1854 (7 March 2024)

<https://www.sciencedirect.com/journal/vaccine/vol/42/issue/7>

*Editorial*

**[AI and the future of vaccine development](#)**

Wayne C. Koff, Anima Anandkumar, Gregory A. Poland

Pages 1407-1408

*Discussion*

**[Addressing cultural and political drivers of vaccine hesitancy: Considerations for the African and Asian contexts](#)**

Khushi Kohli, Bhav Jain, Edward Christopher Dee, Beverly Lorraine Ho

Pages 1411-1413

*Discussion*

**[Safe in pregnancy: A global living systematic review and meta-analysis of COVID-19 vaccines in pregnancy](#)**

Pierre Buekens, Mabel Berrueta, Agustín Ciapponi, Ariel Bardach, ... Andy Stergachis

Pages 1414-1416

*Short communication Open access*

**[Report from the World Health Organization's immunization and vaccines related implementation research advisory committee \(IVIR-AC\) meeting, Geneva, 11–13 September 2023](#)**

Philipp Lambach, Walt Orenstein, Sheetal Silal, Alyssa N. Sbarra, ... Joseph Wu

Pages 1424-1434

*Research article Open access*

**[Attitudes and behaviors of maternal Tdap vaccination in Panama, Peru, and Colombia: An international cross-sectional study](#)**

Pippa McDermid, Katrina Blazek, Nathan Mouglin, Angus Thomson, Holly Seale

Pages 1698-1703

**Vaccines**

<https://www.mdpi.com/journal/vaccines>

[Accessed 16 Mar 2024]

*Latest Articles [Selected]*

*Open Access Communication*

**[Estimating the Impact of Vaccination Campaigns on Measles Transmission in Somalia](#)**

by Niket Thakka

*Open Access Article*

**[Immunization of Children under 2 Years Old in the Coastal Hadhramaut Governorate, Yemen, during Public Health Emergencies: A Trend Analysis of 2013–2020](#)**

by Suha Ali Batarfi,

*Open Access Review*

**[Global Perspectives on the Hepatitis B Vaccination: Challenges, Achievements, and the Road to Elimination by 2030](#)**

by Said A. AlBusafi and Ahmed Alwassief

**Value in Health**

March 2024 Volume 27 Issue 3 p271-382  
<https://www.valueinhealthjournal.com/current>  
[Reviewed earlier]

## **World Development**

Volume 175 March 2024  
<https://www.sciencedirect.com/journal/world-development/vol/175/suppl/C>  
[Reviewed earlier]

.....  
.....

### ***Contents [click to move among sections]***

:: [Milestones, Perspectives](#)  
:: [WHO](#)  
:: [Organization Announcements](#)  
:: [Journal Watch](#)  
:: [Pre-Print Servers](#)

.....  
.....

## ***Pre-Print Servers***

### **Gates Open Research**

<https://gatesopenresearch.org/browse/articles>  
[Accessed 16 Mar 2024]  
*Selected Research*  
[No new digest content identified]

### **medRxiv**

<https://www.medrxiv.org/content/about-medrxiv>  
[Accessed 16 Mar 2024]  
*[Filter: All articles]*

#### **[Forecasting the spatial spread of an Ebola epidemic in real-time: comparing predictions of mathematical models and experts](#)**

James D Munday, Alicia Rosello, W John Edmunds, Sebastian Funk  
medRxiv 2024.03.14.24304285; doi: <https://doi.org/10.1101/2024.03.14.24304285>

#### **[An Analysis of Controlled Human Infection Studies Registered on ClinicalTrials.gov](#)**

Danny Toomey, Jupiter Adams-Phipps, James Wilkinson, John Pietro, Steffen Kamenicek, Daniel Kaufman, Euzebiusz Jamrozik, Joshua Osowicki, Meta Roestenberg, Ian Saldanha  
medRxiv 2024.03.13.24304104; doi: <https://doi.org/10.1101/2024.03.13.24304104>

#### **[Measuring what matters: context-specific indicators for assessing immunisation performance in Pacific Island Countries and Areas](#)**

Cyra Patel, Ginny M Sargent, Adeline Tinessia, Helen Mayfield, Dan Chateau, Akeem Ali, Ilisapeci Tuibeqa, Meru Sheel  
medRxiv 2024.03.12.24304182; doi: <https://doi.org/10.1101/2024.03.12.24304182>

**[Factors associated with human papillomavirus, hepatitis A, hepatitis B and mpox vaccination uptake among gay, bisexual and other men who have sex with men in the UK – findings from the large community-based RiISH-Mpox survey](#)**

George Baldry, Dawn Phillips, Ruth Wilkie, Marta Checchi, Kate Folkard, Ruth Simmons, John Saunders, Sema Mandal, Catherine H Mercer, Hamish Mohammed, Dana Ogaz  
medRxiv 2024.03.08.24303981; doi: <https://doi.org/10.1101/2024.03.08.24303981>

**OSF Pre-prints**

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

*[Provider Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-prints]*

[No new digest content identified]

**Wellcome Open Research**

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 16 Mar 2024]

*Selected Research*

*Research Article Open Access*

**[REVISED COVID-19 and older people's wellbeing in northern KwaZulu-Natal – the importance of relationships \[version 3; peer review: 1 approved with reservations\]](#)**

Thabang Manyapelo, et al.

*Background*

The COVID-19 pandemic and the non-pharmacological prevention methods have affected the wellbeing of older people. In this paper we focus on the wellbeing, and vulnerability, of older people in rural northern KwaZulu-Natal, South Africa during the first year of the pandemic.

\* \* \* \*

**[Think Tanks](#)**

**Brookings** [to 16 Mar 2024]

<http://www.brookings.edu/>

*Research*

*No new digest content identified.*

**Center for Global Development** [to 16 Mar 2024]

<https://www.cgdev.org/>

*All Research [Selected]*

*No new digest content identified.*

**Chatham House** [to 16 Mar 2024]

<https://www.chathamhouse.org/>

*Selected Analysis, Comment, Events*

*No new digest content identified.*

**Council on Foreign Relations** [to 16 Mar 2024]

<https://www.cfr.org/media/news-releases>

*New Releases [Selected]*

*No new digest content identified.*

**CSIS** [to 16 Mar 2024]

<https://www.csis.org/>

*Reports [Selected]*

*No new digest content identified.*

**Kaiser Family Foundation** [to 16 Mar 2024]

[https://www.kff.org/search/?post\\_type=press-release](https://www.kff.org/search/?post_type=press-release)

*Newsroom*

**[Most Parents Haven't Heard Misinformation About the Measles Vaccine though Significant Shares Are Uncertain About the Validity of Claims](#)**

March 14, 2024 News Release

As rates of childhood vaccination decline and with measles on the rise again, a KFF Health Misinformation Tracking Poll, fielded in late February, examines the extent to which adults have heard and believe misinformation about the measles vaccine. The poll also examines the public's views of the U.S. government and...

**McKinsey Global Institute** [to 16 Mar 2024]

<https://www.mckinsey.com/mgi/overview>

*Latest Research*

*No new digest content identified.*

**ODI [Overseas Development Institute]** [to 16 Mar 2024]

<https://odi.org/en/publications/>

*Publications [Selected]*

*No new digest content identified.*

**Pew Research Center** [to 16 Mar 2024]

<https://www.pewresearch.org/>

*Latest Publications [Selected]*

*No new digest content identified.*

**Rand** [to 16 Mar 2024]

<https://www.rand.org/pubs.html>

*Published Research [Selected]*

*No new digest content identified.*

**Urban Institute** [to 16 Mar 2024]

<https://www.urban.org/publications>

**[New Research Publications - Selected](#)**



**World Economic Forum** [to 16 Mar 2024]

<https://agenda.weforum.org/press/>

Media [Selected]

No new digest content identified.

.....

.....

## **Public Consultations/Call for Inputs/Call for Papers**

### **Public consultation of the Global Ethics Charter for the Protection of Healthy Volunteers in Clinical Trials**

Inserm Issued 26 Feb 2024 **Comments due by March 30, 2024.**

The « Global Ethics Charter for the Protection of Healthy Volunteers in Clinical Trials » is a key deliverable of the VoIREthics initiative that was set up to promote ethical guidelines to protect healthy volunteers in biomedical research. The draft Charter, available in English, French and Spanish is open for public comments up to March 30, 2024.

Download the draft Charter (pdf, 201 Ko)

To submit your or your organization's feedback, download the public comment document (docx, 27 Ko). Please email the completed document to [hvworkshop.disc@inserm.fr](mailto:hvworkshop.disc@inserm.fr)

### **Key Information and Facilitating Understanding in Informed Consent; Draft Guidance for Sponsors, Investigators, and Institutional Review Boards**

21 CFR Part 50 [Docket No. FDA-2022-D-2997] **Comments due: 04/30/2024**

*SUMMARY:*

This draft guidance provides recommendations related to two provisions of the revised Federal Policy for the Protection of Human Subjects (the revised Common Rule) by the U.S. Department of Health and Human Services (HHS) and identical provisions in FDA's proposed rule "Protection of Human Subjects and Institutional Review Boards." FDA's proposed rule, if finalized, would harmonize certain sections of FDA's regulations on human subject protections and institutional review boards (IRBs), to the extent practicable and consistent with other statutory provisions, with the revised Common Rule, in accordance with the 21st Century Cures Act (Cures Act). The guidance addresses the provisions of the revised Common Rule that require informed consent to begin with key information about the research and to present information in a way that facilitates understanding and identical provisions in FDA's proposed rule.

\* \* \* \* \*

***Vaccines and Global Health: The Week in Review*** is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

*Copyright GE2P2 Global Foundation 2023. Some Rights Reserved.*

*This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.*

*Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.*

*.....*

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

\* \* \* \* \*  
\* \* \* \* \*